Epithelial-Mesenchymal Transition Signature Markers (EMTsm) with Machine Learning-Based Analysis as a Predictor of Metastatic Prostate Cancer

Prostate cancer (PCa) remains a significant health burden, necessitating improved prognostic tools for optimal management. This Small Business Innovation Research (SBIR) proposal outlines a transformative project aimed at enhancing PCa prognostication through the integration of epithelial-to-mesenchymal transition (EMT) signature markers (EMTsm) with advanced imaging and machine learning techniques. Leveraging our expertise in molecular profiling and digital pathology, we seek to address critical limitations in current prognostic methods, particularly the challenges posed by tumor heterogeneity and sampling errors. By examining EMTsm expression patterns in PCa tissues and correlating them with clinical outcomes, we aim to develop a novel predictive model for metastatic potential in early-stage PCa patients. Our approach involves the analysis of tissue samples from diverse PCa cohorts, including patients with metastatic disease and those with localized tumors. Through the integration of spatial imaging technology and sophisticated machine learning algorithms, we aim to extract clinically relevant features indicative of aggressive PCa behavior. The resulting predictive model will enable clinicians to identify individuals at increased risk of disease progression, facilitating timely intervention and personalized treatment planning. Moreover, by incorporating EMTsm data into our predictive framework, we aim to enhance the accuracy and reliability of PCa prognostication, ultimately improving patient outcomes and reducing healthcare costs. This project aligns closely with the mission of the NIH to support innovative research that addresses significant challenges in healthcare. Through our interdisciplinary approach and collaboration with clinical partners, we aim to translate scientific discoveries into tangible benefits for PCa patients. Furthermore, the development of our predictive model has significant commercial potential, with opportunities for widespread adoption in clinical practice. Overall, this SBIR proposal represents a unique opportunity to advance the field of PCa prognostication and ultimately improve the lives of patients affected by this disease.